Stakeholders regroup after failure of latest AIDS vaccine.
MEXICO CITY -- The development of an AIDS vaccine is likely to take a long time, and research needs to be more selectively focused on the most promising candidate vaccines, given the recent failure of the latest leading candidate to prevent infection in a large, international trial, according to...

InterMune to Present at Deutsche Bank Biotech Boston Confab.
BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST. To access a live audio webcast of the...

Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'.
- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work - "Let's Fight Flu Together!" initiative supports CDC's new vaccination recommendations which include children six months to 18 years old(1) - Campaign goal is...

Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market.
Test Simultaneously Identifies and Differentiates More Virulent 027 Strain from Common Strains SUNNYVALE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cepheid today announced the release of Xpert(TM) C. difficile as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first...

Idenix Pharmaceuticals to Present at Deutsche Bank's 2008 Biotech Boston Confab.
CAMBRIDGE, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that management will present at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11th at 9:40 a.m. ET. The live and archived webcast of the presentation can be accessed under "Calendar of Events" in the...

Novavax Reports Third Quarter 2008 Financial Results.
ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced financial results for the third quarter ended September 30, 2008. Novavax reported a net loss of $7.8 million ($0.12 loss per share) for the third quarter of 2008 compared to a net loss of $9.0 million ($0.15 loss per...

GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update.
ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update. Robert...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C.
BRISBANE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Roche , InterMune, Inc. and Pharmasset today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the first...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C.
PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. , Roche and InterMune, Inc. today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the...

Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial.
AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy...